Become a Reviewer

The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Become a Reviewer >

For Authors

Help enrich communication and advance scientific understanding in cancer immunotherapy.

For Authors >

From the Editors

JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

From the Editors >

JITC Collections

Readers have the opportunity to view JITC's special editions and theme-focused collections.

JITC Collections >

Get to Know JITC's Leadership

Meet the JITC Editors

WIC APAC 2025
Michael T. Lotze, MDJITC Editor-in-Chief 
Monday, July 21 and Tuesday, July 22 in Singapore

Get to know JITC's phenomenal group of editors, lead by Editor-in-Chief, Michael T. Lotze, MD, and Deputy Editor-in-Chief, Sjoerd H. van der Burg, PhD. 

Interested in meeting our editors? From Geneva, Switzerland to National Harbor, Maryland, our editors will be available to meet with you and learn about your research. Check back for more information on Meet-the-Editor opportunities in 2025. 

JITC Awards

Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.

Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.

The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.

APC Discounts

As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC members who are first, last, or corresponding authors on JITC articles at the time of acceptance will receive discounted Article Processing Charges (APCs). This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author. 

JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. 

For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.

Highly Accessed Articles

What is the article Altmetric Attention Score?

Altmetric_Score_donut.pngIndicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

SITC strategic vision: prevention, premalignant immunity, host and environmental factors

Article has an altmetric score of 385
Sasha E Stanton, Kristin G Anderson, Tullia C Bruno, Christian M Capitini, Mary L Disis, Jennifer McQuade, Laszlo Radvanyi, Claire Vanpouille-Box, Jennifer Wargo, Kelly J Baines, Megan M Y Hong, Adnan Rajeh, Raymond H Kim, Phillip Awadalla, Lauren K Hughes and Saman Maleki Vareki


 

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

Article has an altmetric score of 385
Tricia R Cottrell, Michael T Lotze, Alaa Ali, Carlo B Bifulco, Christian M Capitini, Laura Q M Chow, Anthony R Cillo, Deborah Collyar, Leslie Cope, Julie Stein Deutsch, Genia Dubrovsky, Sacha Gnjatic, Denise Goh, Susan Halabi, Gary Kohanbash, Holden T Maecker, Saman Maleki Vareki, Sarah Mullin, Barbara Seliger, Janis Taube, Wim Vos, Joe Yeong, Kristin G Anderson, Tullia C Bruno, Codruta Chiuzan, Ivan Diaz-Padilla, Elizabeth Garrett-Mayer, Isabella C Glitza Oliva, Paola Grandi, Elizabeth G Hill, Brian P Hobbs, Yana G Najjar, Phyllis Pettit Nassi, Virgil H Simons, Sumit K Subudhi, Ryan J Sullivan and Chris H Takimoto


 

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy

Article has an altmetric score of 385
Thomas U Marron, Jason J Luke, Brianna Hoffner, Jane Perlmutter, Connie Szczepanek, Valsamo Anagnostou, Ann W Silk, Pedro J Romero, Elizabeth Garrett-Mayer9 and Leisha A Emens


 

Browse the Current Issue

JITC Collections and Special Issues

Within JITC's full catalog of published articles, a number of collections are available to provide readers with opportunities to view sets of papers following particular themes. 

In celebration of the 40 th Anniversary of the Society for Immunotherapy of Cancer (SITC), the Journal for ImmunoTherapy of Cancer ( JITC ) presents this special series of commentaries from luminaries ...
The rapid clinical and scientific progress of immuno-oncology (IO) since the approval of the first immune checkpoint inhibitors has changed the spectrum of patient care forever. Recognizing the milestones ...
Edited by Alan Hutson, PhD The JITC series “Computational Immuno-Oncology” aims to provide clarity and guidance regarding the discourse on data science technologies and analyses among researchers ...
Edited by Kavita Dhodapkar, MBBS and Johanneke E. A. Portielje, MD, PhD Significant gaps and disparities persist with respect to cancer immunotherapy research across populations and a range of factors, ...
Edited by Neil S. Forbes and Grant McFadden While microbial based therapy is one of the oldest cancer therapy modalities, dating from the 1880s, the field is not well-developed. Even after all this ...
Immune Monitoring Technology Primers 2016 Biomarkers immune monitoring technology primer: Immunoscore® Colon (20 Sept 2016) Immune monitoring technology primer: whole exome sequencing ...
Immune Monitoring Technology Primers 2016 Biomarkers immune monitoring technology primer: Immunoscore® Colon (20 Sept 2016) Immune monitoring technology primer: whole exome sequencing ...
Cancer Immunotherapy Guidelines Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer (28 July 2022) Society ...
Edited by Valsamo Anagnostou, MD, PhD and Mark D. Stewart, PhD Liquid biopsies have become increasingly utilized approaches in cancer research. As they gain momentum as minimally invasive means for ...

Imaging and Immunotherapy

Edited by Elisabeth G.E. de Vries and Lawrence H. Schwartz Novel imaging techniques and analyses have become increasingly utilized tools in cancer research for informing treatment decisions. Their ...